MAN MADE MUSIC FOUNDER
Hailed as "equal parts Philip Glass and Don Draper" by Details Magazine, Joel Beckerman is an award-winning composer and producer for television. He is the founder of Man Made Music, a company specializing in sonic branding. Fast Company named him one of their "Most Creative People in Business" and Man Made Music one of their "Most Innovative Companies" in music. He wrote The Sonic Boom: How Sound Transforms the Way We Think, Feel, and Buy.
PROFESSOR, FOUNDER-HEALTH TECH HUB, CO-FOUNDER OPEN MHEALTH
Deborah is a Professor of Computer Science at Cornell Tech, and a Professor of Public Health at Weill Cornell Medical College. She founded the Health Tech Hub and directs the Small Data Lab at Cornell Tech, which develops new personal data APIs and applications for individuals to harvest the small data traces they generate daily. Deborah is also co-founder of the non-profit startup, Open mHealth.
PFIZER, VP WORLDWIDE INNOVATION
Wendy is also a member of Pfizer's Worldwide Business Development and Innovation Leadership Team. She drives innovative ideas and thinking across the organization through the identification of transformative and disruptive innovation platforms that can be leveraged across the business, and through the development of capabilities and culture that will support continued innovation throughout the organization.
DAVID FISCHELL '75, MS '78, PHD '80
ANGEL MEDICAL SYSTEMS, CEO
A serial entrepreneur who has founded 14 biomedical device companies in the last 20 years, including Angel Medical Systems, a company in the final stage of obtaining FDA approval for an implantable heart attack detection and patient alerting system, David's other companies include eNeura, Inc (2002) Transcranial Magnetic Stimulation systems for Migraine Headaches; NeuroPace, Inc. (1997) implantable brain pacemakers to treat epilepsy and Ablative Solutions (2011) to develop chemical based renal denervation catheters. He currently has 134 issued U.S. patents, and has published numerous papers in the fields of telecommunications, cardiology, radiobiology, and radiation dosimetry. From 1998 until 2005, he was the primary designer of coronary stents, including the BX Velocity™ and Cypher™ Stents for Cordis, a Johnson & Johnson Company now implanted in more than 7 million patients.
FLATIRON HEALTH, CO-FOUNDER
Before co-founding Flatiron Health, Zach was Co-Founder, President & COO of Invite Media, an advertising technology company based in NYC. Invite Media built the industry's first enterprise advertising platform for buying and optimizing online media in real-time. Invite Media was acquired by Google in 2010. Prior to Invite Media, Zach co-founded EatNow.com which was privately acquired. An active angel investor, Zach has invested in over 30 technology startups throughout the country, including Bell Biosystems, Breakthrough.com, Care at Hand, DocPhin, Doctor Evidence, Genomera, Meddik, Oscar, and Predilytics.
AiCURE, CO-FOUNDER & CEO
AiCure is an artificial intelligence company that has developed facial recognition and motion-sensing technology to confirm medication ingestion by clinical trial participants and high-risk patients in real time. Adam is a passionate advocate for the use of healthcare software as a population health tool and has directed much of his previous work to this end. Prior to AiCure, he was responsible for further developing Cerner Corporation’s European strategy and was a Visiting Fellow of eHealth at Imperial College in London, UK. Adam has spoken extensively on the topic of healthcare innovation and has held numerous advisory board positions including for the Indian High Commission’s Healthcare, Pharmaceutical, & Biotech Committee, and for Deloitte Consulting’s Health Informatics Network for Europe (HINE). Adam has been responsible for much of the vision and strategy at AiCure and is the primary inventor of the patented technology. He has acted as a subject-matter expert on medication adherence technologies for the National Institutes of Health (NIH) and is currently a principal investigator for multiple NIH innovation grants.
ACCENTURE, PRINCIPAL DATA SCIENTIST & SENIOR ANALYTICS MANAGER
Design, devleop, and deliver advanced machinelearning and deep learning models. Areas of focus include: behavior modeling and customer segmentation for risk, fraud, adn marketing; text analytics (unstructured), social media monitoring, networking modeling, and optimization models and simulation; Arun will dep dive for us consutling projects for the health ttech adn healthcare industries he has led utilitizing data science.
MEMORIAL SLOAN KETTERING CANCER CENTER
DAVID SOLIT DIRECTOR OF CENTER FOR MOLECULAR ONCOLOGY
David is a Medical Oncologist and a Laboratory Scientist. As a member of the Genitourinary Oncology Service, he specializes in treating cancers of the prostate, bladder, kidneys, testes, and other related cancers with chemotherapy, targeted therapies, immunotherapy, or combinations of these drugs. David is very involved in clinical trials, particularly trials of targeted drugs known as kinase inhibitors. These drugs block pathways inside cancer cells that cause the cells to grow or spread. One area of focus in his research is studying patients who are known as extraordinary responders. These are people with difficult-to-treat cancers who are found to respond exceptionally well to a new drug, even though that drug does not work in most people with the same disease. His laboratory in the Human Oncology and Pathogenesis Program at MSK completed the first whole-genome analysis of a patient with bladder cancer. This patient had a complete and durable response to a novel targeted drug that was only effective in a small minority of patients. By performing this analysis, they were able to determine what was genetically unique about this patients’ tumor. They are now testing the same drug in other patients whose tumors have a similar genetic profile.
As the Director of the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, he lead a multidisciplinary team of clinicians, geneticists, bioinformaticians and laboratory scientists. The mission of the Center for Molecular Oncology is to integrate molecular and clinical information to develop therapies that are individualized to each patient’s cancer. He and his colleagues work to make sure that all patients who come to Memorial Sloan Kettering receive the best care possible, whether that means conventional or experimental therapies.
NICKOLAUS SCHULTZ LEAD DEVELOPER OF CBIO PORTAL FOR CANCER GENOMICS
Nickolaus is an Associate Attending in the Computational Oncology Service in the Department of Epidemiology and Biostatistics at MSK. He received a Ph.D. in Biochemistry from the Free University in Berlin and then trained as a post-doctoral researcher in Computational Biology at MSK. He is also the Head of Knowledge Systems in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO). Here, he leads the development of the cBioPortal for Cancer Genomics, a popular resource for the visualization and analysis of large-scale cancer genomics data sets. The cBioPortal has become an integral part of research and clinical sequencing at MSKC where it serves as the main mechanism by which genomic data is delivered to investigators and clinicians.
His research focuses on identifying the genomic alterations that underlie different types of cancer. He is involved in several projects of The Cancer Genome Atlas (TCGA) and is an investigator in the Stand Up To Cancer (SU2C) Prostate Cancer Dream Team.
Nikolaus Schultz is an Associate Attending in the Computational Oncology Service in the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center (MSK). He received a Ph.D. in Biochemistry from the Free University in Berlin and then trained as a post-doctoral researcher in Computational Biology at MSK.
DAVID HYMAN HEAD OF EARLY CLINICAL DRUG DEVELOPMENT
David is a medical oncologist whose clinical practice is focused on the care of women with gynecologic cancers including ovarian, endometrial, and cervical cancers. In addition, David has a special interest in treating women with uterine sarcomas. He work as part of a multidisciplinary team of surgeons, radiation oncologists, and pathologists who all specialize in the diagnosis and treatment of gynecologic cancers.
His clinical research is focused on developing new treatments for ovarian cancer and uterine sarcomas. He serves as principal investigator on a national research study for women with recurrent uterine sarcoma. He also specializes in early-phase clinical trials (sometimes called Phase I trials). These studies give patients new cancer medicines or new combinations of cancer medicines for the first time. He is working to improve the design of these trials.
JOSE BASELGA PHYSICIAN-IN-CHIEF & CHIEF MEDICAL OFFICER
Jose is a board-certified medical oncologist focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. In clinical practice he cares for women with all stages of breast cancer, and serves as the Physician-in-Chief at MSKCC.
He has devoted over 20 years of his career to the development of therapies against the Epidermal Growth Factor Receptor (EGFR) and the closely related HER2 receptor. In the field of anti-HER2 therapies, he was the lead investigator in the first publication that demonstrated clinical activity of the anti-HER2 monoclonal antibody trastuzumab (Herceptin®) in patients with advanced HER2 over expressing breast cancer. He continues to lead state-of-the-art world-wide clinical trials with trastuzumab including in the neo-adjuvant and adjuvant setting. In the laboratory, he reported the synergy between paclitaxel and trastuzumab that lead to the registration clinical trial. He has also been able to identify a number of mechanisms of resistance to anti-HER2 agents. Some of them including p95HER2 and hyper-activation of the PI3K-Akt-mTOR pathway are therapeutic targets themselves and we are exploring them. Their latest work includes the clinical development of novel anti-HER2 antibodies such as pertuzumab (Perjeta) that have shown to improve the disease free survival and the overall survival in the first line setting. He is currently the principal investigator of the adjuvant clinical trial with pertuzumab. In addition he led the early clinical trials and the pivotal study that lead to the approval of everolimus (Affinitor) in the treatment of patients with hormone receptor positive breast cancer.